Topic：Science  and life--A real adventure

Lecturer：PH.D,  Professor Wang Yanming

 Case  Western Reserve University, US.

Location：Conference  room on 4th floor in Administration Building

                   Fuyan Mountain Campus

Time：10:00  am, 21st September 2017

Dr.  Yanming Wang has a broad research experience in medicinal chemistry in general  and molecular imaging in particular. Following his PhD in chemistry at the Swiss  Federal Institute of Technology (ETH) in Zurich, Switzerland, Dr. Wang conducted  his postdoctoral research at Duke University. In 1998, Dr. Wang joined the  faculty of Radiology at the University of Pittsburgh where his research was  focused on radiopharmaceutical development for imaging studies. Over the past  decade, his research has focused on the development and application of molecular  probes for biomedical imaging based on a variety of imaging modalities including  positron emission tomography (PET), single photon emission computed tomography  (SPECT), magnetic resonance imaging (MRI), multiphoton microscopy, and  near-infrared fluorescent imaging (NIRF). He has developed several imaging  agents targeting some important pathological processes such as amyloid  deposition in Alzheimer’s disease and aging, myelin damage and repair in  multiple sclerosis, DNA damage and repair as well as MET receptor expression in  cancer. He was the first to design and synthesize PIB, an amyloid-imaging agent  that has now been widely used in clinical trials worldwide. He is also noted for  his recent work on longitudinal imaging of myelination based on multiple imaging  modalities.In addition, Dr. Wang is Director of Radiopharmaceutical Research at  Case Western Reserve University and provides imaging agents for many clinical  and preclinical studies.  

Over  the past 15 years, Dr. Yanming Wang’s research has been focused on the  development and application of molecular probes for biomedical imaging based  onPET,  SPECT, MRI, multiphoton microscopy, and near-infrared fluorescent imaging. He  has developed several imaging agents targeting some important disease processes  including amyloid deposition in Alzheimer’s disease, myelin damage and repair in  multiple sclerosis, DNA damage and repair as well as MET receptor expression in  cancer. He was the co-inventor of PIB, an amyloid-imaging agent that has now  been widely used in clinical trials worldwide. He is considered as a pioneer in  PET imaging of myelination.